{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:58:27Z","timestamp":1781074707638,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04066-y","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:13:42Z","timestamp":1778120022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the long-term hydroxychloroquine\u2019s effects on COVID-19 outcomes in patients with autoimmune diseases: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Heba M.","family":"Amal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Maher Galal","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Osman","family":"Abdel-Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Said","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omayma Anwar","family":"Khorshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walla\u2019a A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"4066_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108427","volume":"215","author":"K Yuki","year":"2020","unstructured":"Yuki K, Fujiogi M, Koutsogiannaki S (2020) COVID-19 pathophysiology: a review. Clinical Immunology 215:108427","journal-title":"Clinical Immunology"},{"issue":"2","key":"4066_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s11481-020-09923-w","volume":"15","author":"P Pahan","year":"2020","unstructured":"Pahan P, Pahan K (2020) Smooth or risky revisit of an old malaria drug for COVID-19? J Neuroimmune Pharmacol 15(2):174\u2013180","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"4066_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery 6(1):1\u20134","journal-title":"Cell discovery"},{"key":"4066_CR4","doi-asserted-by":"crossref","unstructured":"Singh AK, Singh A, Singh R, Misra A (2020) Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes & metabolic syndrome: Clinical research & reviews. ;14(4):589\u2009\u2013\u200996","DOI":"10.1016\/j.dsx.2020.05.017"},{"issue":"2","key":"4066_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/jopcs.jopcs_12_20","volume":"2","author":"M Sahu","year":"2021","unstructured":"Sahu M, Kumar A, Shankar SH, Patidar D, Vishwakarma VK, Sahoo P et al (2021) Insights into the Mechanisms of Action of Chloroquine and Hydroxychloroquine and its Use in COVID-19 for Chemoprophylaxis. J Prim Care Specialties 2(2):27\u201332","journal-title":"J Prim Care Specialties"},{"issue":"7","key":"4066_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41419-020-2721-8","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E et al (2020) Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis 11(7):512","journal-title":"Cell Death Dis"},{"key":"4066_CR7","doi-asserted-by":"crossref","unstructured":"Riley RD, Higgins JP, Deeks JJ (2011) Interpretation of random effects meta-analyses. BMJ. ;342","DOI":"10.1136\/bmj.d549"},{"key":"4066_CR8","doi-asserted-by":"crossref","unstructured":"Srinivasjois R (2021) Fixed and random-effects models for meta-analysis. Principles and practice of systematic reviews and meta-analysis. Springer, pp 73\u201378","DOI":"10.1007\/978-3-030-71921-0_7"},{"key":"4066_CR9","unstructured":"Jpt H (2008) Cochrane handbook for systematic reviews of interventions. http:\/\/www.cochrane-handbookorg"},{"issue":"6","key":"4066_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00296-021-04857-9","volume":"41","author":"ZA Alzahrani","year":"2021","unstructured":"Alzahrani ZA, Alghamdi KA, Almaqati AS (2021) Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. Rheumatol Int 41(6):1097\u20131103","journal-title":"Rheumatol Int"},{"issue":"4","key":"4066_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4103\/injr.injr_327_20","volume":"16","author":"SV Annamalai","year":"2021","unstructured":"Annamalai SV, Santhanam S, Mohanasundaram K, Nambi T, Sankaran S, Natarajan R et al (2021) COVID-19 and Rheumatic Diseases in Tamil Nadu-A Multicenter Retrospective Observational Study. Indian J Rheumatol 16(4):441\u2013446","journal-title":"Indian J Rheumatol"},{"issue":"9","key":"4066_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14442","volume":"75","author":"S Bat\u0131bay","year":"2021","unstructured":"Bat\u0131bay S, Ko\u00e7ak Ulucak\u00f6y R, \u00d6zdemir B, G\u00fcnendi Z, G\u00f6\u011f\u00fc\u015f FN (2021) Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: a single\u2010centre experience from Turkey. International Journal of Clinical Practice 75(9):e14442","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"4066_CR13","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s10067-021-05675-x","volume":"40","author":"G Espinosa","year":"2021","unstructured":"Espinosa G, Prieto-Gonz\u00e1lez S, Llevadot M, Marco-Hern\u00e1ndez J, Mart\u00ednez-Artu\u00f1a A, P\u00e9rez-Isidro A et al (2021) The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. Clin Rheumatol 40(5):2057\u20132063","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4066_CR14","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1016\/S2665-9913(20)30305-2","volume":"2","author":"CA Gentry","year":"2020","unstructured":"Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ (2020) Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol 2(11):e689\u2013e97","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"4066_CR15","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40744-021-00373-1","volume":"8","author":"D Guillaume","year":"2021","unstructured":"Guillaume D, Magalie B, Sina E, Imene S-M, Frederic V, Mathieu D et al (2021) Antirheumatic drug intake influence on occurrence of COVID-19 infection in ambulatory patients with immune-mediated inflammatory diseases: a cohort study. Rheumatol Therapy 8(4):1887\u20131895","journal-title":"Rheumatol Therapy"},{"issue":"4","key":"4066_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmi.2020.12.003","volume":"27","author":"S-Y Jung","year":"2021","unstructured":"Jung S-Y, Kim M-S, Kim M-C, Choi S-H, Chung J-W, Choi ST (2021) Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. Clin Microbiol Infect 27(4):611\u2013617","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"4066_CR17","doi-asserted-by":"publisher","first-page":"e0249036","DOI":"10.1371\/journal.pone.0249036","volume":"16","author":"J Mac\u00edas","year":"2021","unstructured":"Mac\u00edas J, Gonz\u00e1lez-Moreno P, S\u00e1nchez-Garc\u00eda E, Morillo-Verdugo R, P\u00e9rez-Venegas JJ, Pinilla A et al (2021) Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. PLoS ONE 16(4):e0249036","journal-title":"PLoS ONE"},{"key":"4066_CR18","doi-asserted-by":"crossref","unstructured":"Mollaeian A, Kim DS, Haas CJ (2021) COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. Open Rheumatol J. ;15(1)","DOI":"10.2174\/1874312902115010069"},{"issue":"1","key":"4066_CR19","doi-asserted-by":"publisher","first-page":"rkab014","DOI":"10.1093\/rap\/rkab014","volume":"5","author":"K Pham","year":"2021","unstructured":"Pham K, Torres H, Satlin MJ, Goyal P, Gulick RM (2021) Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. Rheumatol Adv Pract 5(1):rkab014","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"4066_CR20","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.jaad.2020.10.098","volume":"84","author":"LK Rangel","year":"2021","unstructured":"Rangel LK, Shah P, Sicco KL, Caplan AS, Femia A (2021) Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis. J Am Acad Dermatol 84(6):1769\u20131772","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4066_CR21","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S2665-9913(20)30378-7","volume":"3","author":"CT Rentsch","year":"2021","unstructured":"Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP et al (2021) Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol 3(1):e19\u2013e27","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"4066_CR22","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.21608\/ejhm.2022.270499","volume":"89","author":"A Sobh","year":"2022","unstructured":"Sobh A, Elegezy M, Mofreh M, El-nagdy AH, Tohlob M, Elnagdy MH et al (2022) Role of hydroxychloroquine in rheumatoid arthritis and systemic lupus erythematosus patients during COVID-19 pandemic. Egypt J Hosp Med 89(2):6589\u20136595","journal-title":"Egypt J Hosp Med"},{"issue":"7","key":"4066_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/annrheumdis-2021-221636","volume":"81","author":"MF Ugarte-Gil","year":"2022","unstructured":"Ugarte-Gil MF, Alarc\u00f3n GS, Izadi Z, Duarte-Garc\u00eda A, Re\u00e1tegui-Sokolova C, Clarke AE et al (2022) Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis 81(7):970\u2013978","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4066_CR24","doi-asserted-by":"publisher","first-page":"030006052210903","DOI":"10.1177\/03000605221090363","volume":"50","author":"IA Walbi","year":"2022","unstructured":"Walbi IA, Albarqi HA, Alghanim NS, Albadi MA, Al Maimouni HM, Alkahtani SA et al (2022) Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. J Int Med Res 50(4):03000605221090363","journal-title":"J Int Med Res"},{"issue":"1","key":"4066_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mco2.56","volume":"2","author":"C Ye","year":"2021","unstructured":"Ye C, Zhong J, Cai S, Dong L, Li C, Hou X et al (2021) COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province. China MedComm 2(1):82\u201390","journal-title":"China MedComm"},{"issue":"12","key":"4066_CR26","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/art.41450","volume":"72","author":"R Fernandez-Ruiz","year":"2020","unstructured":"Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R et al (2020) Leveraging the United States epicenter to provide insights on COVID\u201019 in patients with systemic lupus erythematosus. Arthritis Rheumatol 72(12):1971\u20131980","journal-title":"Arthritis Rheumatol"},{"issue":"21","key":"4066_CR27","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"RC Group","year":"2020","unstructured":"Group RC (2020) Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 383(21):2030\u20132040","journal-title":"N Engl J Med"},{"issue":"24","key":"4066_CR28","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1001\/jama.2020.8630","volume":"323","author":"ES Rosenberg","year":"2020","unstructured":"Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J et al (2020) Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 323(24):2493\u20132502","journal-title":"JAMA"},{"issue":"8","key":"4066_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s11739-020-02505-x","volume":"15","author":"L Ayerbe","year":"2020","unstructured":"Ayerbe L, Risco-Risco C, Ayis S (2020) The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. Intern Emerg Med 15(8):1501\u20131506","journal-title":"Intern Emerg Med"},{"key":"4066_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.9734\/jpri\/2020\/v32i830468","volume":"32","author":"AS Ali","year":"2020","unstructured":"Ali AS, Abdel-Rahman MS, Almalikil RS, Mohamed AS, Alfaifi KA, Fadil AE et al (2020) Optimizing the use of hydroxychloroquine in the management of COVID-19 given its pharmacological profile. J Pharmaceut Res Int 32:29\u201343","journal-title":"J Pharmaceut Res Int"},{"issue":"6","key":"4066_CR31","doi-asserted-by":"publisher","first-page":"106007","DOI":"10.1016\/j.ijantimicag.2020.106007","volume":"55","author":"H Derendorf","year":"2020","unstructured":"Derendorf H (2020) Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Int J Antimicrob Agents 55(6):106007","journal-title":"Int J Antimicrob Agents"},{"key":"4066_CR32","doi-asserted-by":"crossref","unstructured":"Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. ;369","DOI":"10.1136\/bmj.m1849"},{"issue":"1","key":"4066_CR33","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","volume":"12","author":"C Axfors","year":"2021","unstructured":"Axfors C, Schmitt AM, Janiaud P, Van\u2019t Hooft J, Abd-Elsalam S, Abdo EF et al (2021) Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 12(1):2349","journal-title":"Nat Commun"},{"key":"4066_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","volume":"97","author":"S Arshad","year":"2020","unstructured":"Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K et al (2020) Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 97:396\u2013403","journal-title":"Int J Infect Dis"},{"issue":"5","key":"4066_CR35","doi-asserted-by":"publisher","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","volume":"55","author":"J Fantini","year":"2020","unstructured":"Fantini J, Di Scala C, Chahinian H, Yahi N (2020) Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 55(5):105960","journal-title":"Int J Antimicrob Agents"},{"issue":"22","key":"4066_CR36","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.3390\/jcm11226865","volume":"11","author":"I Landsteiner de Sampaio Am\u00eandola","year":"2022","unstructured":"Landsteiner de Sampaio Am\u00eandola I, Aires Pinheiro J, Povoa P, C\u00e9s de Souza Dantas V, Serafim RB (2022) COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis. J Clin Med 11(22):6865","journal-title":"J Clin Med"},{"issue":"5","key":"4066_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/imj.15202","volume":"51","author":"T Eviatar","year":"2021","unstructured":"Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S et al (2021) Prevalence of COVID\u201019 and seroprevalence to SARS\u2010CoV\u20102 in a rheumatologic patient population from a tertiary referral clinic in Israel. Intern Med J 51(5):682\u2013690","journal-title":"Intern Med J"},{"issue":"10","key":"4066_CR38","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00296-020-04676-4","volume":"40","author":"F Montero","year":"2020","unstructured":"Montero F, Mart\u00ednez-Barrio J, Serrano-Benavente B, Gonz\u00e1lez T, Rivera J, Molina Collada J et al (2020) Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 40(10):1593\u20131598","journal-title":"Rheumatol Int"},{"issue":"8","key":"4066_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/ajhp\/zxab056","volume":"78","author":"N Awad","year":"2021","unstructured":"Awad N, Schiller DS, Fulman M, Chak A (2021) Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection. Am J Health-System Pharm 78(8):689\u2013696","journal-title":"Am J Health-System Pharm"},{"issue":"21","key":"4066_CR40","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","volume":"383","author":"AB Cavalcanti","year":"2020","unstructured":"Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LC, Veiga VC, Avezum A et al (2020) Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med 383(21):2041\u20132052","journal-title":"N Engl J Med"},{"issue":"25","key":"4066_CR41","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G et al (2020) Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 382(25):2411\u20132418","journal-title":"N Engl J Med"},{"issue":"7","key":"4066_CR42","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1089\/aid.2015.0336","volume":"32","author":"JM Jacobson","year":"2016","unstructured":"Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC et al (2016) The effect of chloroquine on immune activation and interferon signatures associated with HIV-1. AIDS Res Hum Retroviruses 32(7):636\u2013647","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4066_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","volume":"195","author":"M Torigoe","year":"2018","unstructured":"Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y (2018) Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol 195:1\u20137","journal-title":"Clin Immunol"},{"key":"4066_CR44","doi-asserted-by":"crossref","unstructured":"Horby P, White NJ, Landray MJ (2021) Hydroxychloroquine in hospitalized patients with Covid-19. Reply. N Engl J Med 384(9)","DOI":"10.1056\/NEJMc2035374"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04066-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04066-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04066-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:16:59Z","timestamp":1781072219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04066-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4066"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04066-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}